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ABSTRACT 
Background: In the Reduction of Endpoints in Non-Insulin-Dependent Dia- 
betes Mellitus with the Angiotensin II Antagonist Losartan (RENAAL) study, 
the primary composite nd point was the 2-fold increase in baseline serum crea- 
tinine concentration, the development of end-stage renal disease (ESRD), or 
death. The effects of losartan used for the prevention or delay of progression of 
diabetic nephropathy to ESRD were compared with those of conventional nti- 
hypertensive treatment (control) (calcium channel blockers, diuretics, ¢z-blockers, 
[3-blockers, and centrally acting agents), but not angiotensin-converting e zyme 
(ACE) inhibitors or angiotensin II antagonists (AIIAs), in 1513 adults with type 2 
diabetes mellitus (DM-2) and nephropathy. Both treatment groups received 
conventional ntihypertensive therapy (calcium channel blockers, diuretics, 
cz-blockers, [3-blockers, and/or centrally acting agents). ACE inhibitors and AIIAs 
were not allowed during the study period. The relative risk (RR) for composite 
outcome was 25% less, and the RR for ESRD was 28% less, in the losartan- 
treated group compared with the control group. 
Objective: The aim of this retrospective cost-effectiveness analysis was to 
use data from the RENAAL study to determine the survival benefits and lifetime 
direct medical costs of a losartan-based regimen for the prevention of ESRD in 
patients with DM-2 and nephropathy in the setting of the UK National Health 
Service (NHS). 
Methods: This analysis used life-years aved as the effectiveness measure. 
The effect of losartan-based treatment on ESRD risk was confined to the trial 
period (3.5 years). However, survival and the lifetime direct medical costs of 
managing ESRD were projected beyond the trial period to incorporate the full 
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effects of ESRD on survival and resource use. The effect of altering key variables 
was examined using 1-way sensitivity analyses. 
Results: ESRD-related costs were significantly lower in patients receiving 
losartan-based treatment compared with those in the control group (savings per 
patient, £7390 [95% CI, £11,366-£3414; P < 0.001] [£1 = US -$1.75]). Incorporation 
of the cost of losartan into the assessment found reduced net costs (savings per 
patient, £6622 [95% CI, £10,591-£2653; P = 0.001]). The projected mean number of 
life years saved due to ESRD risk reduction with losartan was 0.44 years (95% CI, 
0.16-0.71; P = 0.002). Losartan treatment was found to save costs in all cases, even 
if the cost of renal replacement therapy for patients with ESRD was reduced by 50%. 
Conclusion: In this retrospective cost-effectiveness analysis using data from 
the RENAAL study, losartan-based treatment for the prevention or delay of pro- 
gression of diabetic nephropathy to ESRD in patients with DM-2 and nephrop- 
athy was found to be potentially cost saving compared with conventional nti- 
hypertensive therapy from the perspective of the UK NHS. (Curr Ther Res Clin 
Exp. 2005;66:475-485) Copyright © 2005 Excerpta Medica, Inc. 
Key words: losartan, economic analysis, diabetic nephropathy, end-stage r nal 
disease, ESRD, cost. 
INTRODUCTION 
Type 2 diabetes mellitus (DM-2) affects -3% to 6% of the UK adult population, 
and its prevalence is increasing due to the increasing age and rate of obesity in 
the population. 1 Approximately 37,500 patients in the United Kingdom receive 
renal replacement therapy (peritoneal dialysis, hemodialysis, or transplanta- 
tion) each year, 1 and this number increases by -7% annually. 1 Each year, dia- 
betic nephropathy is associated with 18% of the new cases of patients requiring 
renal replacement therapy. 1 Length and quality of life are significantly reduced 
in patients whose condition progresses to end-stage renal disease (ESRD). 1 
In recent years, angiotensin II antagonists (AIIAs) have been studied for the 
control of blood pressure (BP) in patients with DM-2 and nephropathy. The 
Reduction of Endpoints in Non-Insulin-Dependent Diabetes Mellitus with the 
Angiotensin II Antagonist Losartan (RENAAL) study 2was a randomized, ouble- 
blind trial comparing an antihypertensive regimen based on losartan (50-100 mg 
QD) with a regimen of conventional ntihypertensive tr atment (control) (cal- 
cium channel blockers, diuretics, s-blockers, [3-blockers, and centrally acting 
agents), but not angiotensin-converting e zyme (ACE) inhibitors or AIIAs, in 
1513 adults with DM-2 and nephropathy (losartan group, 751 patients; control 
group, 762 patients). The mean duration of follow-up was 3.4 years. The design 
and results of the study have been reported previously. 2,3 Briefly, the RENAAL 
study 2found that adding losartan potassium to the conventional therapy regi- 
men significantly reduced the relative risk (RR) for the primary composite nd 
point (a 2-fold increase in serum creatinine concentration [SCr], development 
of ESRD [defined as the need for dialysis or transplantation], or death) by 25% 
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and reduced the RR for progression to ESRD by 28% compared with controls 
(P = 0.006 and 0.002, respectively). Moreover, the clinical benefits of losartan 
treatment exceeded those attributable to BP reduction alone. 
In the Irbesartan Diabetic Nephropathy Trial 4 in 1715 patients with estab- 
lished neuropathy, irbesartan reduced the RR for the pr imary composite nd 
point (2-fold increase in SCr, progression to ESRD, or death) by 20% compared 
with placebo and by 23% compared with amlodipine besylate (P = 0.02 and 
0.006, respectively). The results from these 2 large studies suggest hat AIIAs 
might have a major role in the management of DM-2 and renal disease. 
We previously reported on a within-trial analysis of the economic implica- 
tions of the results from the RENAAL study on the population of patients with 
DM-2 in the United Kingdom. 5Over a prespecif ied time frame of 3.5 years, losar- 
tan use was associated with a reduction in the number of ESRD days (time from 
ESRD onset to death or end of study) by 33.6 days per patient at risk. As a result, 
losartan was associated with a net cost savings of £2515 per patient (£1 = 
US -$1.75) over 3.5 years. These cost savings increased to £3721 over 4 years. 
Net savings were first realized at 2 years, the point at which ESRD-related cost 
savings (£543 per patient) more than offset losartan drug costs (£442 per 
patient). It was concluded that a losartan-based regimen might provide sub- 
stantial cost savings compared with conventional treatment alone in the setting 
of the UK National Health Service (NHS). 
The previous report based on the clinical findings of the RENAAL trial 2 was 
confined to the economic effects of the reduction of ESRD within the trial 
period. 5No attempt was made to extrapolate the cost benefits beyond the trial 
period to the lifetime of the patient or to model the economic effects of an on- 
going differential health benefit. 
Thus, the present article reports an extension of the earlier cost-savings analy- 
sis. We examined the long-term costs (in terms of the lifetime direct medical 
costs of managing ESRD) and survival benefits of a losartan-based regimen for 
the prevention of ESRD in patients with DM-2 and nephropathy. 
MATERIALS AND METHODS 
This analysis of data from the RENAAL study 2 used life-years aved (LYSs) as 
the measure of cost-effectiveness. The assessment was conducted from the per- 
spective of the UK NHS (direct medical costs). 
End Points 
The assessment combined aspects of a within-trial economic assessment 
and a lifetime projection of treatment benefit observed during the trial. The 
effects of losartan-based treatment on ESRD risk was confined to the trial 
period. No additional clinical benefit in ESRD risk was projected beyond the 
trial, and the costs of losartan medication were confined to the trial period or 
until a patient developed ESRD. However, survival and the lifetime direct medi- 
477 
CURRENT THERAPEUTIC RESEARCH 
cal costs of managing ESRD experienced during the trial were projected beyond 
the trial period to incorporate the full effects of ESRD on survival and resource 
use. This approach was similar to that used in the West of Scotland Coronary 
Prevention Study economic evaluation. 6 
It was conservatively assumed that there were no differences in the costs of 
nonstudy medications between the 2 treatment groups. 2We assumed that pa- 
tients who discontinued study medication incurred no additional costs. We did 
not include the costs associated with monitoring SCr and potassium concen- 
tration because this monitoring would be performed routinely in patients with 
DM-2 and renal disease. The costs of treating complications associated with 
dialysis were also excluded from the analysis. 
Calculations 
The cost of losartan treatment was estimated from the unit cost of losartan 
to the UK NHS multiplied by average number of days of treatment at different 
doses during the RENAAL study. 2
The lifetime cost of ESRD (base-case analysis) was based on an annual average 
cost for hemodialysis and peritoneal dialysis 1weighted according to the distri- 
bution of first renal replacement therapy, adjusted to 2004 prices, and the median 
survival time of patients undergoing diabetic renal replacement therapy age- 
matched to the RENAAL population. 7 The annual costs of hemodialysis and 
peritoneal dialysis were obtained from the UK Transplant Web site. 1 As a sec- 
ondary analysis, the costs of hemodialysis and peritoneal dialysis from the UK 
2-center European Dialysis and Cost-Effectiveness (EURODICE) study 8were used. 
The number of LYSs was estimated by multiplying the absolute risk reduc- 
tion for ESRD in the losartan arm by the additional life-years expected by pre- 
venting ESRD during the trial period. Life-years gained by preventing/delaying 
ESRD was calculated as the difference in life expectancy between patients with 
and without ESRD. These life expectancies were estimated by means of Weibull 
models applied to the RENAAL data, 2 with baseline severity of proteinuria s a 
covariate. Assessments of uncertainty (95% CIs) were derived using a nonpara- 
metric "bootstrap" analysis. 9 
Costs were adjusted to 2004 prices, and costs and life-years were discounted 
at a rate of 3.5%. The following variables were used in 1-way sensitivity analy- 
ses: cost of daily renal replacement therapy using bottom-up and, alternatively, 
top-down costing from EURODICE; reducing the cost of daily renal replacement 
therapy by 50% (bottom-up costing); and increasing the life expectancy by 50% 
with losartan on dialysis. 
RESULTS 
The weighted annual average cost of dialysis as reported on the UK Transplant 
Web site 1 and used in the base-case analysis was £30,000. This cost represents 
£20,000 annually for peritoneal dialysis (30% of patients receiving dialysis) and 
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£34,500 annually for hemodialysis (70%). Data from the EURODICE study found 
a weighted average annual cost of £23,864 using top-down costing and £17,657 
using bottom-up costing (Table I). 8 
Costs and cumulative incidence of ESRD and LYSs are presented in Table II. 
Losartan significantly reduced ESRD-related costs (savings per patient, £7390 
[95% CI, £11,366-£3414; P < 0.001]), resulting in a significantly reduced net cost 
(savings per patient, £6622 [95% CI, £10,591-£2653; P = 0.001]). The estimate of a 
mean of 0.44 LYS (95% CI, 0.16-0.71; P = 0.002) with losartan therapy is in the con- 
text of a median survival time of 2.4 years after initiation of renal replacement 
therapy for diabetic patients age-adjusted to the RENAAL population. 7 
Results concerning costs and LYSs for the base-case and 4 sensitivity analy- 
ses found that losartan treatment was cost saving in all cases, even if the cost of 
renal replacement therapy was reduced by 50% (bottom-up costing) (Table 111). 
The assumption of a 50% increase in life expectancy after dialysis in patients 
receiving losartan resulted in per-patient total cost savings (£101) that was sta- 
tistically similar to that of conventional therapy, with an increase in overall ife- 
years gained over the base-case analysis. A lifetime projection of ESRD, costs, 
and LYSs showed a reduction of 0.176, or 17%, in the cumulative incidence of 
ESRD, a reduction in total cost of £5483 per patient, and an increase of 0.67 LYS 
with losartan use. 
DISCUSSION 
The results of this analysis suggest hat a losartan-based drug regimen in 
patients with DM-2 and nephropathy was projected to be cost saving from the 
perspective of the UK NHS because it reduced the incidence of ESRD compared 
Table I. Costs of renal replacement herapy at 2 centers in the United Kingdom (2004 
data) .8, 
Parameter Top-Down, £ Bottom-Up, £ Difference, £ 
Peritoneal dialysis 
Center 1 17,408 1 6,677 731 
Center 2 14,456 1 3,506 950 
Mean 15,977 15,092 - 
Hemodialysis 
Center 1 25,221 18,880 6341 
Center 2 26,303 1 7,668 8635 
Mean 25,672 18,274 - 
Weighted 
Annual 23,864 1 7,657 6207 
Daily 65.34 48.34 17 
*£1 = US -$1.75. 
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Table III. Net cost savings and life-years saved (LYSs) by using Iosartan-based therapy 
versus conventional therapy alone in the base-case and sensitivity analyses.* 
Parameter Net Cost Savings, £ LYSs 
Base case 
Value 6622 0.44 
95% CI 2653 to 10,591 0.16 to 0.71 
EURODICE bottom-up costing 
Value 3507 Same as base case 
95% CI 1214 to 5800 - 
EURODICE top-down costing 
Value 5010 Same as base case 
95% CI 1907 to 8113 - 
Reduce renal replacement herapy 
costs by 50% 
Value 2927 Same as base case 
95% CI 985 to 4869 - 
Increase life expectancy with Iosartan 
on dialysis by 50% 
Value 101 0.58 
95% CI -4695 to 4897 0.34 to 0.82 
Continued benefits and costs 
beyond trial 
Value 5483 0.67 
95% CI -983 to 11,949 0.04 to 1.3 
EURODICE = European Dialysis and Cost-Effectiveness tudy. 8 
*£1 = US -$1.75. 
with a non-ACE inhibitor/non-AliA ant ihypertensive r gimen. These findings 
are important  for public health. ESRD is a source of substantial,  long-term mor- 
bidity in an area of health care in which there is an unmet need in the United 
Kingdom. 1° Strategies to prevent or delay ESRD could reduce the lengths of 
transplantat ion waiting lists and demands on dialysis units. 
The base-case analysis was based on a broad est imate of the costs of renal 
replacement therapy across the United Kingdom. However, the sensit ivity 
analyses, based on data from 2 centers, suppor ted  the base-case analysis with 
the finding of net cost savings with losartan-based therapy across a wide range 
of conditions, including a conservat ive (bottom-up) est imate of renal replace- 
ment therapy costs. 
A limitation of this analysis was that median life expectancy after initiation of 
dialysis was used to est imate lifetime renal rep lacement  cost because mean 
data were unavailable. For this reason, and because mean survival would be 
expected to be higher than median survival, the results were considered con- 
servative. Another limitation was the omission of costs related to complica- 
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tions of dialysis. Infectious complications in patients receiving long-term hemo- 
dialysis are common, particularly Staphylococcus aureus bacteremia. 11,12 Engemann 
et a111 reported the mean cost of treating S aureus bacteremia in a tert iary care 
setting in the United States to be US $24,034 per episode. Due to the omission 
of these costs in our analysis, the actual costs of the non- losar tan-based 
therapy might be significantly underestimated. 
The results of the present analysis agree with those from previously pub- 
lished cost analyses with the use of losartan-based therapy. The first, a within- 
trial assessment based on the RENAAL trial, reported a significantly higher net 
cost savings of $3522 per patient over 3.5 years with the use of losartan-based 
treatment compared with conventional treatment (95% CI, $143-$6900; P = 
0.041). 13 In Switzerland, a cost-effectiveness analysis of RENAAL data using a deci- 
sion analytic model revealed a net cost savings of CHF 4084 (£2687) in patients 
with DM-2 and nephropathy who received losartan 50 to 100 mg of QD for 
3.5 years compared with conventional therapy alone. 14 
In England and Wales, the National Institute for Clinical Excellence recom- 
mends routine use of ACE inhibitors in patients with DM-2 and nephropathy. 15 
In the Micro-Heart Outcomes Prevention Evaluation substudy, 16 the largest rial 
(3577 patients) of an ACE inhibitor in patients with diabetes and renal disease to 
date, ramipril use was associated with decreased progression of microalbumin- 
uria to overt nephropathy but not reduced prevalence of ESRD. A systematic 
review of 9 trials comparing the effects of ACE inhibitors with those of placebo 
found no statistically significant effect on the rate of progression to ESRD. 17 
International guidelines, such as those of the Joint National Committee on 
Prevention, Detection, Evaluation, and Treatment of High Blood Pressure and 
the National High Blood Pressure Education Program Coordinating Committee 18 
and the American Diabetes Association, 19 recommend that hypertensive or normo- 
tensive patients with diabetic nephropathy receive an ACE inhibitor or AIIA as 
first-line treatment. Some evidence suggests that a combination of ACE inhibi- 
tion with AII antagonism might effect clinical benefits. A meta-analysis of stud- 
ies comparing combination treatment with an ACE inhibitor plus an AIIA with 
each component  alone identified 8 studies in patients with varying degrees of 
proteinuria t baseline. An additional 30% reduction in proteinuria was noted 
over ACE inhibition alone and 39% over monotherapy with an AIIA. 2° However, 
these studies were not specifically focused on patients with diabetes. There is 
clearly a need for more data to guide treatment decisions. 
At present, the relative cost-effectiveness of losartan versus ACE inhibitors 
in patients with DM-2 and nephropathy is unknown due to a lack of data con- 
cerning the extent o which ACE inhibitors delay the need for renal replacement 
therapy in this patient population. Similarly, the relative effects of ACE in- 
hibitors and AIIAs on survival are unknown because of a lack of adequate trials 
directly comparing these 2 drug classes. 16 The cost-effectiveness of initiating 
treatment earlier in the course of the disease was assessed by Palmer et al. 21 
In that analysis, early irbesartan treatment was projected to increase life ex- 
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pectancy and reduce costs in hypertensive patients with DM-2 and microal- 
buminuria. Life and cost savings were also projected in patients with overt 
nephropathy. Compared with conventional treatment, when irbesartan was ini- 
tiated early and late, modelled savings ranged from $11.9 million to $3.3 million 
per 1000 patients, respectively. 
The availability of effective medical treatment to reduce the risk for progres- 
sion to ESRD has important implications for public health. ESRD is a common 
cause of morbidity and mortality; DM-2 is a common cause of ESRD. A treatment 
shown to reduce ESRD risk in patients with DM-2 could reduce the lengths of 
transplantation waiting lists and the demand for other types of renal replace- 
ment therapy, including the various types of dialysis. 
CONCLUSION 
In this retrospective cost-effectiveness analysis using data from the RENAAL 
study, losartan-based treatment for the prevention or delay of progression to 
ESRD in patients with DM-2 and nephropathy was found to be potential ly cost 
saving compared with conventional ant ihypertensive therapy from the per- 
spective of the UK NHS. 
ACKNOWLEDGMENTS 
Jiten Vora, FRCP, was an investigator in the RENAAL study, and has received 
grants from Merck Sharp & Dohme Ltd. for work on advisory boards and speak- 
ing engagements. George Carides, PhD, and Paul Robinson, FFPM, may hold 
stock in Merck & Co., Inc. 
The authors thank Catherine Barnes, BSc, and Duncan Chambers, PhD, for 
their assistance in preparing the manuscript, and Hege Urdhal, PhD, for helpful 
comments.  
REFERENCES 
1. UK Transplant. Fact sheet: The cost-effectiveness of transplantation. London, UK: UK 
Transplant; 2003. Available at: www.uktransplant.org.uk. Accessed January 28, 2005. 
2. Brenner BM, Cooper ME, de Zeeuw D, et al, for the RENAAL Study Investigators. 
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 dia- 
betes and nephropathy. NEngl JMed. 2001;345:861-869. 
3. Brenner BM, Cooper ME, de Zeeuw D, et al, for the RENAAL Study Investigators. The 
losartan renal protection study--rationale, study design and baseline characteris- 
tics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist 
Losartan). J Renin Angiotensin Aldosterone Syst. 2000; 1:328-335. 
4. Lewis E J, Hunsicker LG, Clarke WR, et al, for the Collaborative Study Group. 
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients 
with nephropathy due to type 2 diabetes. NEngl JMed. 2001;345:851--860. 
5. Vora JP, Robinson P J, O'Hare P, et al. Economic implications of the RENAAL study in 
the United Kingdom. Diabet Med. 2003;20(Suppl 2):89. 
483 
CURRENT THERAPEUTIC RESEARCH 
6. Caro J, Klittich W, McGuire A, et al. The West of Scotland coronary prevention study: 
Economic benefit analysis of primary prevention with pravastatin. BMJ. 1997;315: 
1577-1582. 
7. Scottish Renal Association. Scottish Renal Registry Report, 2001. Edinburgh, Scot- 
land: Scottish Renal Association Information and Statistics Division; 2004. 
8. Wordsworth S, Ludbrook A. Comparability of costing across countries: Does the 
approach matter? Presented at: Developing Economic Evaluation Methods (DEEM) 
Meeting; April 15-16, 2003; Aberdeen, UK. Available at: http://www.herc.ox.ac.uk/ 
DEEM/Aberdeen/Wordsworth.pdf. Accessed February 1, 2005. 
9. Efron B, Tibshirani RJ. An Introduction to the Bootstrap. New York, NY: Chapman and 
Hall; 1993. 
10. US Dept of Health and Human Services (DHHS). National service framework for renal 
disease [DHHS Web site]. Available at: http://www.dh.gov.uk/assetRoot/04/07/05/25/ 
04070525.pdf. Accessed November 27, 2005. 
11. Engemann J J, Friedman JY, Reed SD, et al. Clinical outcomes and costs due to 
Staphylococcus aureus bacteremia among patients receiving long-term hemodialysis. 
Infect Control Hosp Epidemiol. 2005;26:534-539. 
12. Metcalfe W, Khan IH, Prescott G J, et al. Hospitalization i the first year of renal 
replacement therapy for end-stage renal disease. QJM. 2003;96:899-909. 
13. Herman WH, Shahinfar S, Carides GW, et al. Losartan reduces the costs associated 
with diabetic end-stage renal disease: The RENAAL study economic evaluation. 
Diabetes Care. 2003;26:683-687. 
14. Szucs TD, Sandoz MS, Keusch GW. The cost-effectiveness of losartan in type 2 diabet- 
ics with nephropathy in Switzerland--an analysis of the RENAAL study. Swiss Med 
Wkly. 2004;134:440-447. 
15. National Institute for Clinical Excellence (NICE). Management of type 2 diabetes. 
Renal disease: Prevention and early management [NICE Web site]. Available at: 
http://www.nice.org.uk/pdf/diabetesrenalguideline.pdf. Accessed December 1, 2005. 
16. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on 
cardiovascular nd microvascular outcomes in people with diabetes mellitus: Re- 
suits of the HOPE study and MICRO-HOPE substudy [published correction appears 
in Lancet. 2000;356:860]. Lancet. 2000;355:253-259. 
17. Strippoli GF, Craig M, Deeks JJ, et al. Effects of angiotensin converting enzyme 
inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes 
in diabetic nephropathy: Systematic review. BMJ. 2004;329:828. 
18. Chobanian AV, Bakris GL, Black HR, et al, for the National Heart, Lung, and Blood 
Institute Joint National Committee on Prevention, Detection, Evaluation, and 
Treatment of High Blood Pressure and the National High Blood Pressure Education 
Program Coordinating Committee. The Seventh Report of the Joint National 
Committee on Prevention, Detection, Evaluation, and Treatment of High Blood 
Pressure: The JNC 7 report [published correction appears in JAMA. 2003;290:197]. 
JAMA. 2003;289:2560-2572. 
19. Arauz-Pacheco C, Parrott MA, Raskin P, for the American Diabetes Association. 
Treatment of hypertension i  adults with diabetes. Diabetes Care. 2003;26(Suppl 1): 
$80-$82. 
20. Doulton TW, He F J, MacGregor GA. Systematic review of combined angiotensin- 
converting enzyme inhibition and angiotensin receptor blockade in hypertension. 
Hypertension. 2005;45:880--886. 
21. Palmer AJ, Annemans L, Roze S, et al. Cost-effectiveness of early irbesartan treat- 
ment versus control (standard antihypertensive m dications excluding ACE inhibi- 
484 
J. Vora et aL 
tots, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel 
blockers) or late irbesartan treatment inpatients with type 2 diabetes, hypertension, 
and renal disease. Diabetes Care. 2004;27:1897-1903. 
Address correspondence to: Jiten Vora, FRCP, Royal Liverpool Hospital, Prescot 
Street, Liverpool L7 8XP, United Kingdom. E-mail: Jiten.Vora@rlbuht.nhs.uk 
485 
